TuberculosisNCT05805878
KAP Regarding Tuberculosis Among Physicians in Assiut City
An observational study of Tuberculosis, run by Assiut University at 1 site in Egypt.
Trial summary
To Strengthen tuberculosis education and awareness among physicians in Assiut city in the framework of national tuberculosis control program. Read more about this study
- Who is it for?
- Ages 26 to 40 years
- Conditions the study is for
- Tuberculosis
- How many people
- 296 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2024to 27 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 26 to 40 years
- All sexes
- Adult
Study population: Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.
Who may be able to join
- Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.
Who cannot join
- specialist Physicians
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Knowledge, Attitudes and Practices Regarding Tuberculosis Among Physicians in Assiut City
To Strengthen tuberculosis education and awareness among physicians in Assiut city in the framework of national tuberculosis control program.
Read the detailed description
Tuberculosis (TB) remains a major global health problem. According to the World Health Organization (WHO), an estimated global total of 10.6 million people fell ill with TB in 2021, equivalent to 134 cases per 100 000 populations. About 1.5 million people die from TB each year - making it the 13th leading cause of death worldwide . Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above human immunodeficiency virus (HIV). TB is present in all countries but it is highly prevalent among the low socioeconomic section of the population and marginalized sections of the community .
TB is an infectious bacterial disease caused by Mycobacterium tuberculosis (Mtb), which is transmitted between humans through the respiratory route and most commonly affects the lungs, but can damage any tissue . Only about 10 percent of individuals infected with Mtb progress to active TB disease within their lifetime; the remainder of persons infected successfully contain their infection. One of the challenges of TB is that the pathogen persists in many infected individuals in a latent state for many years and can be reactivated to cause disease. According to WHO, approximately one-quarter of the world's population is latently infected with Mtb . The risk of progression to TB disease after infection is highest soon after the initial infection and increases dramatically for persons co-infected with HIV or other immune-compromising conditions .
TB is a curable and preventable disease. TB drugs are administered in different combinations of four first-line drugs which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) long treatment duration, (iv) non adherence to drug regimen and (v) evolution of drug-resistant TB strains. Drug-resistant TB(DR-TB) poses a significant challenge to TB therapy and control programs .
In 2014 and 2015, all Member States of WHO and the United Nations (UN) committed to ending the TB epidemic, through their adoption of WHO's End TB Strategy and the UN Sustainable Development Goals (SDGs). The UN SDGs include ending the TB epidemic by 2030 under Goal 3. WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030, and ensure that no family is burdened with catastrophic health expenditure due to TB.
In Egypt TB is still a health problem, which affects the young active age group with pulmonary TB more in Lower Egypt, whereas extrapulmonary cases were more in Upper Egypt, especially in the rural community . Egypt is ranked among the mid-level incidence countries and according to a WHO estimation of the TB burden in 2019, the incidence of TB was 12 per 100 000 inhabitants . The Ministry of Health and Population (MOHP) has established the National Tuberculosis Control Program(NTP) in 1979 .
The COVID-19 pandemic has undone decades of progress in the fight against TB. Globally, the estimated number of deaths from TB increased between 2019 and 2021, reversing years of decline between 2005 and 2019. The burden of DR-TB is also estimated to have increased between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB . The most obvious and immediate impact was a large global drop in the reported number of people newly diagnosed with TB. Reductions in the reported number of people diagnosed with TB in 2020 and 2021 suggest that the number of people with undiagnosed and untreated TB has grown, resulting in an increased number of TB deaths and more community transmission of infection and increased numbers of people developing TB .
Healthcare workers (HCWs) play a fundamental role in the global fight against TB . Adequate basic knowledge about TB enables the physician to suspect and deal with a TB case, whereas insufficient knowledge will lead to either escaping suspicion or improper dealing with a TB case. The delayed proper diagnosis and management of TB will cause spreading of TB and facilitate the development of resistance to anti-TB drugs .
Worldwide, many studies found that HCWs have important knowledge gaps in relation to TB diagnosis, treatment and infection prevention and control; have some negative attitudes and stigma connected with the disease; and engage in poor practices, all of which contribute to their increased risk of infection and negative impacts on patients and the community .
In Egypt, previous studies illustrated lower basic knowledge of the studied primary health care (PHC) physicians about TB. In Gharbia Governorate , the mean of satisfactory basic knowledge was 49.6%. Similar results were detected in Menofya Governorate and in Qalyubia Governorate, where the means of satisfactory basic knowledge of the studied physicians about TB were 54.5% and 48.2% respectively. Other study in Behaira Governorate reported a mean of 63% for physicians' knowledge.
- Conditions
- Tuberculosis
- Medical subject headings
- Tuberculosis
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess knowledge, attitudes and practices (KAP) on tuberculosis among physicians working in Assiut city.
questionnaire will be used to assess this outcome measure.
Measured: 3 years
Secondary outcomes (1)
To explore the factors associated with the physicians' knowledge, attitudes and practices regarding tuberculosis.
questionnaire will be used to assess this outcome measure
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2023
- Study start1 Jun 2024
- Primary completion25 Nov 2024
- Study completion27 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 296 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Esraa Abd Elkareem Mariae Mohamed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05805878
- Sponsor's protocol ID
- KAP regarding Tuberculosis
- Status last verified
- Oct 2026
- First submitted
- 22 Mar 2023
- Last updated
- 28 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020 Jun;128(6):1547-1567. doi: 10.1111/jam.14478. Epub 2019 Oct 29.
PubMed 31595643Vigenschow A, Edoa JR, Adegbite BR, Agbo PA, Adegnika AA, Alabi A, Massinga-Loembe M, Grobusch MP. Knowledge, attitudes and practices regarding tuberculosis amongst healthcare workers in Moyen-Ogooue Province, Gabon. BMC Infect Dis. 2021 May 27;21(1):486. doi: 10.1186/s12879-021-06225-1.
PubMed 34039304
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Knowledge, Attitudes and Practices Regarding Tuberculosis Among Physicians in Assiut City
- ClinicalTrials.gov ID
- NCT05805878
- Acronym / sponsor ID
- KAP regarding Tuberculosis
- Conditions
- Tuberculosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 296 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 25 Nov 2024 (actual)
- Study completion
- 27 Jul 2026 (actual)
- First posted
- 10 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To Strengthen tuberculosis education and awareness among physicians in Assiut city in the framework of national tuberculosis control program.
Detailed description
Tuberculosis (TB) remains a major global health problem. According to the World Health Organization (WHO), an estimated global total of 10.6 million people fell ill with TB in 2021, equivalent to 134 cases per 100 000 populations. About 1.5 million people die from TB each year - making it the 13th leading cause of death worldwide . Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above human immunodeficiency virus (HIV). TB is present in all countries but it is highly prevalent among the low socioeconomic section of the population and marginalized sections of the community .
TB is an infectious bacterial disease caused by Mycobacterium tuberculosis (Mtb), which is transmitted between humans through the respiratory route and most commonly affects the lungs, but can damage any tissue . Only about 10 percent of individuals infected with Mtb progress to active TB disease within their lifetime; the remainder of persons infected successfully contain their infection. One of the challenges of TB is that the pathogen persists in many infected individuals in a latent state for many years and can be reactivated to cause disease. According to WHO, approximately one-quarter of the world's population is latently infected with Mtb . The risk of progression to TB disease after infection is highest soon after the initial infection and increases dramatically for persons co-infected with HIV or other immune-compromising conditions .
TB is a curable and preventable disease. TB drugs are administered in different combinations of four first-line drugs which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) long treatment duration, (iv) non adherence to drug regimen and (v) evolution of drug-resistant TB strains. Drug-resistant TB(DR-TB) poses a significant challenge to TB therapy and control programs .
In 2014 and 2015, all Member States of WHO and the United Nations (UN) committed to ending the TB epidemic, through their adoption of WHO's End TB Strategy and the UN Sustainable Development Goals (SDGs). The UN SDGs include ending the TB epidemic by 2030 under Goal 3. WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030, and ensure that no family is burdened with catastrophic health expenditure due to TB.
In Egypt TB is still a health problem, which affects the young active age group with pulmonary TB more in Lower Egypt, whereas extrapulmonary cases were more in Upper Egypt, especially in the rural community . Egypt is ranked among the mid-level incidence countries and according to a WHO estimation of the TB burden in 2019, the incidence of TB was 12 per 100 000 inhabitants . The Ministry of Health and Population (MOHP) has established the National Tuberculosis Control Program(NTP) in 1979 .
The COVID-19 pandemic has undone decades of progress in the fight against TB. Globally, the estimated number of deaths from TB increased between 2019 and 2021, reversing years of decline between 2005 and 2019. The burden of DR-TB is also estimated to have increased between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB . The most obvious and immediate impact was a large global drop in the reported number of people newly diagnosed with TB. Reductions in the reported number of people diagnosed with TB in 2020 and 2021 suggest that the number of people with undiagnosed and untreated TB has grown, resulting in an increased number of TB deaths and more community transmission of infection and increased numbers of people developing TB .
Healthcare workers (HCWs) play a fundamental role in the global fight against TB . Adequate basic knowledge about TB enables the physician to suspect and deal with a TB case, whereas insufficient knowledge will lead to either escaping suspicion or improper dealing with a TB case. The delayed proper diagnosis and management of TB will cause spreading of TB and facilitate the development of resistance to anti-TB drugs .
Worldwide, many studies found that HCWs have important knowledge gaps in relation to TB diagnosis, treatment and infection prevention and control; have some negative attitudes and stigma connected with the disease; and engage in poor practices, all of which contribute to their increased risk of infection and negative impacts on patients and the community .
In Egypt, previous studies illustrated lower basic knowledge of the studied primary health care (PHC) physicians about TB. In Gharbia Governorate , the mean of satisfactory basic knowledge was 49.6%. Similar results were detected in Menofya Governorate and in Qalyubia Governorate, where the means of satisfactory basic knowledge of the studied physicians about TB were 54.5% and 48.2% respectively. Other study in Behaira Governorate reported a mean of 63% for physicians' knowledge.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 26 to 40 years
- Sex
- All
- Age groups
- Adult
- Study population
- Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.
Key inclusion criteria (1 listed)
- Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.
Key exclusion criteria (1 listed)
- specialist Physicians
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess knowledge, attitudes and practices (KAP) on tuberculosis among physicians working in Assiut city.
Time frame: 3 years
questionnaire will be used to assess this outcome measure.
1 secondary outcome
To explore the factors associated with the physicians' knowledge, attitudes and practices regarding tuberculosis.
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Background: PubMed 31595643Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020 Jun;128(6):1547-1567. doi: 10.1111/jam.14478. Epub 2019 Oct 29.
- Background: PubMed 34039304Vigenschow A, Edoa JR, Adegbite BR, Agbo PA, Adegnika AA, Alabi A, Massinga-Loembe M, Grobusch MP. Knowledge, attitudes and practices regarding tuberculosis amongst healthcare workers in Moyen-Ogooue Province, Gabon. BMC Infect Dis. 2021 May 27;21(1):486. doi: 10.1186/s12879-021-06225-1.
Related trials for Tuberculosis
Active, not recruitingObservational study
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Nontuberculous Mycobacteria, Mycobacterium Tuberculosis
RecruitingObservational study
Training Protocol on the Natural History of Tuberculosis
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Active, not recruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.
Tuberculosis (TB)
RecruitingObservational study
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant Tuberculosis (MDR-TB)
RecruitingObservational study
Biomarker Analysis for Diagnosing and Treatment Monitoring in Extrapulmonary Tuberculosis Patients in Nairobi, Kenya
Tuberculosis, Extrapulmonary Tuberculosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tuberculosis, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess knowledge, attitudes and practices (KAP) on tuberculosis among physicians working in Assiut city. (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05805878, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026; AzTrials last refreshed its copy on 30 Oct 2026.